Advice about Adverse Event (Side Effects) Reporting

At Cadila Pharmaceuticals, we are committed to providing world-class medicines at an affordable cost to the last man standing in society. We understand the need and importance of monitoring drug safety – right from the discovery of the medicine to the entire life cycle of the drug. Cadila Pharmaceuticals tries to ensure that correct information regarding safe and rational use of medicines is assimilated to the public

If you wish to report an adverse event occurring with any of our drug, please read below:

  • Overdose


  • Accidental use


  • Abuse and misuse


  • Medication errors


  • Use of drug during breast feeding


  • Paternal exposure


  • Lack of efficacy


  • Unexpected therapeutic or clinical benefit


  • Use of drug in unapproved indication


  • Use of drug during pregnancy


  • Drug interactions


What to report:

All types of adverse events (side effects occurring after administration of drug)

Other scenario/situations (even if not associated with adverse event)

Where to report:

Sarkhej-Dholka Road, Bhat, Ahmedabad-382 210, INDIA.
Phone : +91-2718-251334
Fax : +91-2718-225039

Contact details for adverse event reporting:

  • For Side-effects Reporting in India: Toll free Number – 18005325326, Press Option 2 for Side effect reporting.


Report even if:

You are not certain whether the medicine caused an adverse reaction or not

You don’t have all the required details


In accordance with the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 and global privacy policies , we inform you that Cadila Pharmaceuticals Limited [here in referred as CPL] (with headquarter in Corporate Campus, Bhat, Sarkhej-Dholka Road, Ahmedabad – 382210, Gujarat, India) will use your personal data voluntarily provided by you only with the consent and in compliance with the principles dictated by the European Regulations on the protection of personal data for processing the Scientific & Medical information which is to be used for assessment of safety of the CPL products in humans.